Glaukos Stock Quote and Company Information

Glaukos is a medical technology company that develops and commercializes minimally invasive therapies for the treatment of glaucoma and other eye conditions.

Glaukos was founded in 2003 by Peter Salgo and Thomas Wells. The company's flagship product is the iStent, a tiny device inserted into the eye to reduce intraocular pressure.

Glaukos is a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol GKOS.

Glaukos stock has experienced significant price fluctuations over the past year, with a 52-week high of $163.71 and a 52-week low of $83.90.

The stock's beta is 1.05, indicating a slightly higher level of volatility compared to the market average. Its 1-month change is 5.64%, and its 3-month change is 15.14%.

The 1-year change is a whopping 75.38%, and the 3-year change is an even more impressive 193.80%. The 5-year change is 167.92%, and the change since the IPO is 411.47%.

Here's a breakdown of the stock's performance compared to the industry and market:

Glaukos has exceeded both the US Medical Equipment industry and the US Market over the past year. Its 1-year return is significantly higher than the industry's return of 16.5% and the market's return of 22.7%.

A fresh viewpoint: Tata Steel Stock Quote

The company's revenue estimates for 2025 are $479 million, with an average estimate of 15 analysts. The revenue estimates for 2026 are $610 million, also with an average estimate of 13 analysts.

Glaukos' key statistics include a revenue (TTM) of $360.347 million, an EPS (TTM) of -$2.96, and a beta of 0.61. Its 3-year Sharpe ratio is 1.16, and its 3-year Sortino ratio is 2.24.

The current share price of Glaukos is a whopping $159.68, which is a significant increase from its 52-week low of $83.90.

Glaukos' beta of 1.05 indicates that the stock is slightly more volatile than the overall market.

Over the past year, Glaukos' stock has seen an impressive 75.38% change, outperforming the market significantly.

Here's a quick rundown of Glaukos' stock performance over different time periods:

Glaukos' stock has seen a 5.64% change in the past month, and a 15.14% change over the past three months.

Suggestion: Twitter Ticker Symbol Change

Glaukos' financial performance is reflected in its revenue, which has reached $360.347 million (TTM). This is a significant figure that indicates the company's ability to generate revenue.

The company's earnings per share (EPS) over the past four quarters have been -$2.96, which may raise some concerns about its profitability. However, it's essential to consider this metric in the context of the company's overall performance.

Glaukos' beta of 0.61 suggests that its stock price is less volatile compared to the overall market. This could be a positive factor for investors who want to reduce their exposure to market fluctuations.

The 3-Year Sharpe Ratio of 1.16 and 3-Year Sortino Ratio of 2.24 indicate that the company's stock has provided a relatively high return over the past three years, considering the level of risk taken.

Here are some key statistics that summarize Glaukos' financial performance:

Glaukos' stock price has been relatively stable, with a volatility percentage of 22.11. This suggests that the stock price may not be subject to extreme fluctuations.

Glaukos has a few notable earnings reports scheduled in the coming months. The Q4 2024 Earnings Release is expected on February 20, 2025.

The company's past earnings reports have shown some volatility, with actual EPS ranging from -0.110 USD to -1.000 USD. You can see a breakdown of these past earnings reports below:

Let's take a look at Glaukos' calendar. They have a number of earnings reports scheduled.

Their Q4 2024 earnings release is expected to be around -0.376 USD.

Glaukos has a steady stream of earnings reports throughout the year.

You can see their upcoming earnings reports in the table below:

In the past, Glaukos has had its fair share of earnings reports and annual general meetings. The company's actual earnings per share (EPS) has been a mixed bag, with some quarters showing losses and others showing a slight profit.

One notable trend is that Glaukos has consistently reported negative EPS in most of its earnings reports. This is evident in the Q3 2024 Earnings Release, where the actual EPS was -0.390 USD.

Here's a breakdown of some of the key past events for Glaukos:

Glaukos has also had its fair share of annual general meetings, with the most recent one taking place on 05/30/2024, where the actual EPS was -2.780 USD.